周五盘后交易中，AbCellera Biologics（ABCL）股价大涨5.37%，引起投资者关注。这一显著涨幅可能与分析师的最新评级有关。
据报道，斯迪富分析师Stephen Willey维持对AbCellera Biologics的买入评级，目标价保持在7美元。这一积极的评级可能提振了投资者信心，推动了股价在盘后交易中的上涨。
值得注意的是，根据TipRanks的数据，Stephen Willey分析师近一年的总胜率为43.8%，总平均回报率为6.8%。虽然这些数据仅供参考，但可能对一些投资者的决策产生影响。投资者在做出投资决策时，仍需谨慎考虑多方面因素，全面评估公司基本面和市场风险。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.